On October 7, GENFLEET-B fell 5.12% in regular trading, trading at HK$31.5/share, with Turnover of HK$1.537 million.

The decline was driven by news pressure from a significant shareholder reduction and a limited company buyback. On September 24, Ourea Biotech HK Limited sold 6 million shares on-market at an average price of HK$27.3, involving approximately HK$164 million, reducing its long position from 6.34% to 4.64%. The fact that the holding fell below the 5% disclosure threshold was interpreted by the market as institutional investors becoming more cautious about the company's short-term valuation. Meanwhile, the company's cumulative H-share buyback in September totaled only about 988,000 shares, which was not sufficient to offset the selling pressure from the reduction.

GENFLEET-B is a China-based company focused on innovative drug development for oncology, autoimmune diseases, and inflammatory diseases. Its R&D platform covers target discovery, molecular evaluation, translational science, clinical development, and key CMC processes. The company operates primarily in domestic and overseas markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)